3- (1- (1- (benzo(d)oxazol- 2- yl)- 2- methylpropyl)- 1H- 1,2,3- triazol- 4- yl)- N- hydroxyacrylamide

a histone deacetylase inhibitor; structure in first source

Also Known As:

NK-HDAC-1

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzoxazoles: 68
      - 3-(1-(1-(benzo(d)oxazol-2-yl)-2-methylpropyl)-1H-1,2,3-triazol-4-yl)-N-hydroxyacrylamide: 3
Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Hydroxamic Acids: 239
      - 3-(1-(1-(benzo(d)oxazol-2-yl)-2-methylpropyl)-1H-1,2,3-triazol-4-yl)-N-hydroxyacrylamide: 3
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Hydroxamic Acids: 239
      - 3-(1-(1-(benzo(d)oxazol-2-yl)-2-methylpropyl)-1H-1,2,3-triazol-4-yl)-N-hydroxyacrylamide: 3

Experts

1.	Shen, Jie: 3 articles (08/2013 - 04/2012)
2.	Guo, Weikang: 2 articles (08/2013 - 04/2012)
3.	Shi, Yi-Kang: 2 articles (07/2013 - 04/2012)
4.	Wang, Peng George: 2 articles (07/2013 - 04/2012)
5.	Cao, Xuefeng: 1 article (08/2013)
6.	Hu, Fanlei: 1 article (08/2013)
7.	Jin, Jin: 1 article (08/2013)
8.	Li, Minghui: 1 article (08/2013)
9.	Li, Zhanguo: 1 article (08/2013)
10.	Liu, Xu: 1 article (08/2013)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 07/01/2013 - "In the present study, we examined the antitumor effects of NK-HDAC-1 on breast cancer in vitro and in vivo. " 07/01/2013 - "The results suggested that NK-HDAC-1 may be a promising therapeutic candidate in treating human breast cancer." 07/01/2013 - "NK-HDAC-1 promoted apoptosis in MDA-MB-231 breast cancer cells by activating both the intrinsic and the extrinsic pathway NK-HDAC-1 at doses of 3, 10 and 30 mg/kg reduced the tumor volume in MDA-MB-231 xenografts by 25.9, 48.8 and 63.6%, respectively. " 07/01/2013 - "Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer."
2.	Rheumatoid Arthritis 08/01/2013 - "The purpose of this study is to investigate the therapeutic effects of a novel histone deacetylase inhibitor (HDACi), NK-HDAC-1, on collagen-induced arthritis (CIA) and pathogenic fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA). "
3.	Experimental Arthritis 08/01/2013 - "Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes." 08/01/2013 - "The purpose of this study is to investigate the therapeutic effects of a novel histone deacetylase inhibitor (HDACi), NK-HDAC-1, on collagen-induced arthritis (CIA) and pathogenic fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA). "
4.	Neoplasms (Cancer) 04/12/2012 - "For the in vitro safety tests, NK-HDAC-1 was far less toxic to nontransformed cells than tumor cells and showed no significant inhibition activity against CYP-3A4. " 07/01/2013 - "NK-HDAC-1 promoted apoptosis in MDA-MB-231 breast cancer cells by activating both the intrinsic and the extrinsic pathway NK-HDAC-1 at doses of 3, 10 and 30 mg/kg reduced the tumor volume in MDA-MB-231 xenografts by 25.9, 48.8 and 63.6%, respectively. "
5.	Arthritis (Polyarthritis) 08/01/2013 - "NK-HDAC-1 is a novel HDACi that may ameliorate inflammatory arthritis by regulating the activation, apoptosis, and inflammatory responses of FLSs. " 08/01/2013 - "CIA was established in DBA/1 mice, and NK-HDAC-1 or vehicle was administered daily after the onset of arthritis. "

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Therapeutic Uses